- Home
- NUV vs VCEL Comparison
NUV vs VCEL Comparison
Compare NUV & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUV | VCEL |
|---|---|---|
| Founded | 1987 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | NUV | VCEL |
|---|---|---|
| Price | $8.94 | $36.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.50 |
| AVG Volume (30 Days) | 464.9K | ★ 684.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $146.18 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $7.86 | $29.24 |
| 52 Week High | $9.08 | $63.00 |
Technical Indicators
Market Signals| Indicator | NUV | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 44.40 |
| Support Level | $8.95 | $34.79 |
| Resistance Level | $9.03 | $37.11 |
| Average True Range (ATR) | 0.05 | 1.30 |
| MACD | -0.02 | -0.27 |
| Stochastic Oscillator | 2.00 | 31.95 |
Price Performance
Historical ComparisonAbout NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.